Effect of dehydroepiandrosterone on bone mass, serum lipids, and dimethylbenz(a)anthracene-induced mammary carcinoma in the rat.
The present study investigated the effect of dehydroepiandrosterone (DHEA) on bone mass and serum lipids in the rat with dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma. The animals received DHEA once daily, percutaneously, at the dose of 5, 10, or 20 mg for 9 months following a single dose of 20 mg DMBA at 50-52 days of age. Bone mineral content (BMC) and bone mineral density (BMD) of total skeleton, lumbar spine, and femur were measured by dual energy x-ray absorptiometry. A 9-month treatment with DHEA increased BMC and BMD of total skeleton by 14.2% to 14.5% (all P < 0.01) and 6.7% to 8.3% (all P < 0.01), respectively. Similarly, femoral BMC and BMD were stimulated by 13.6% to 14.7% (all P < 0.05) and by 8.1% to 9.5% (all P < 0.01), respectively. In addition, BMD of lumbar spine was increased by 10.4% to 10.8% (all P < 0.05), whereas the 9.4% to 11.1% increment in BMC of lumbar spine was not statistically significant. Treatment with DHEA led to 26% (NS), 60% (P < 0.01), and 62% (P < 0.01) decreases in serum triglyceride levels at the same doses. On the other hand, no significant change in serum cholesterol concentrations was observed. Two hundred and seventy-nine days after DMBA administration, the incidence of mammary carcinoma had decreased from 95% in control animals to 73% (P < 0.05), 57% (P < 0.01), and 38% (P < 0.01) at the daily percutaneous doses of 5, 10, and 20 mg of DHEA, respectively. Moreover, the mean tumor number per tumor-bearing animal and the mean tumor area per tumor-bearing animal were also reduced by the same treatments. DHEA increased serum total alkaline phosphatase activity and decreased urinary calcium excretion, but had no effect on the urinary ratio of hydroxyproline to creatinine and urinary phosphorus excretion. These data show that DHEA exerts a stimulatory effect on bone mass and an inhibitory effect on serum triglycerides, as well as a preventive effect on the development of mammary carcinoma induced by DMBA in the rat. Such data suggest that while decreasing the risk of breast cancer, DHEA replacement therapy could also exert beneficial effects on the bone and lipid metabolism in women receiving DHEA replacement therapy.
Luo
S
S
MRC Group in Molecular Endocrinology, CHUL Research Center and Laval University, Quebec, Canada.
Labrie
C
C
Bélanger
A
A
Labrie
F
F
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000633:toxicity*; D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D002118:Calcium / Q000652:urine; D002273:Carcinogens / Q000633:toxicity*; D002784:Cholesterol / Q000097:blood; D003687:Dehydroepiandrosterone / Q000097:blood / Q000494:pharmacology*; D013196:Dihydrotestosterone / Q000097:blood; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000097:blood; D005260:Female; D005269:Femur / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D008055:Lipids / Q000097:blood*; D008159:Lumbar Vertebrae / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D008325:Mammary Neoplasms, Experimental / Q000097:blood / Q000139:chemically induced / Q000503:physiopathology*; D010758:Phosphorus / Q000652:urine; D051381:Rats; D017207:Rats, Sprague-Dawley; D013739:Testosterone / Q000097:blood; D014280:Triglycerides / Q000097:blood
D002273:Carcinogens; D008055:Lipids; D014280:Triglycerides; D013196:Dihydrotestosterone; D010758:Phosphorus; D013739:Testosterone; D003687:Dehydroepiandrosterone; D004958:Estradiol; D015127:9,10-Dimethyl-1,2-benzanthracene; D002784:Cholesterol; D000469:Alkaline Phosphatase; D002118:Calcium